Skip to main content
Premium Trial:

Request an Annual Quote

EMBL Licenses Tripos Software

NEW YORK (GenomeWeb News) — The European Molecular Biology Laboratory has signed a license for two of Tripos' software platforms for use in its chemical biology research, the company said today.

The agreement covers Tripos' ligand-receptor docking and virtual screening software, the Surflex-Dock, and its Themis software for use in drug discovery research.

EMBL will use the software in research at the Chemical Biological Core Facility, which is a collaboration between EMBL and the German Cancer Research Center in Heidelberg and the University of Heidelberg.

EMBL has already used the Surflex-Dock software on EMBL's Linux grid of 1,400 CPUs, and five million structures from EMBL's compound database were docked into a binding site of a receptor structure. This work was completed in "about two days and yielded a promising pool of candidates for experimental testing," the company said.

Joe Lewis, who is head of the Chemical Biology Core Facility, said in a statement that the Themis software already has "provided interesting new chemical ideas contributing to new drug discovery projects."

Financial terms of the agreement were not released.

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.